2024
Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis
Armstrong A, Soliman A, Gisondi P, Fang S, Patel M, Strober B. Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis. Dermatology And Therapy 2024, 1-11. PMID: 39453596, DOI: 10.1007/s13555-024-01293-y.Peer-Reviewed Original ResearchDermatology Life Quality IndexSkin clearanceIndirect comparisonsStatic Physician's Global AssessmentRisankizumab-treated patientsPhysician global assessmentTreatment of psoriasisMatching-adjusted indirect comparisonIndividual patient dataLife Quality IndexPlaque psoriasisPsoriasis AreaRisankizumabDeucravacitinibNew therapiesIntroductionDespite advancesPsO.Global assessmentQuality of lifePsoriasisPatientsPropensity scorePatient dataClearanceHealthcare providers
2023
Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry
Strober B, Ferris L, Callis Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. Real-world effectiveness of risankizumab in patients with moderate-to-severe psoriasis using the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 90: 82-90. PMID: 37739267, DOI: 10.1016/j.jaad.2023.08.097.Peer-Reviewed Original ResearchDermatology Life Quality Index scoresLife Quality Index scoresPsoriasis RegistryQuality Index scoresSevere psoriasisPsoriasis symptomsClear skinIndex scoreReal-world treatment effectivenessPrior biologic treatmentSevere plaque psoriasisInflammatory skin diseasePatient-reported outcomesEntire study populationReal-world effectivenessSignificant reductionPlaque psoriasisEligible adultsPatient adherenceBiologic treatmentActivity impairmentObservational studyStudy populationRisankizumabPsoriasis43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Strober B, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Armstrong A. 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 89: ab189. DOI: 10.1016/j.jaad.2023.07.756.Peer-Reviewed Original Research44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Photowala H, Patel M, Garg V, Strober B. 44047 Long Term Real-World Treat-to-Target Skin Clearance and Maintenance of Response with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2023, 89: ab62. DOI: 10.1016/j.jaad.2023.07.251.Peer-Reviewed Original Research
2022
34940 Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Strober B, Ferris L, Duffin K. 34940 Real-world patient-reported outcomes with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab101. DOI: 10.1016/j.jaad.2022.06.438.Peer-Reviewed Original Research34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry
Armstrong A, Ferris L, Duffin K, Janak J, Sima A, Eckmann T, Patel M, Photowala H, Garg V, Strober B. 34820 Real-world treat-to-target skin clearance with risankizumab in patients with moderate to severe psoriasis from the CorEvitas Psoriasis Registry. Journal Of The American Academy Of Dermatology 2022, 87: ab200. DOI: 10.1016/j.jaad.2022.06.833.Peer-Reviewed Original ResearchLong‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis
Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J, Soliman A, Kaufmann C, Kaplan B, Photowala H, Strober B. Long‐term, durable, absolute Psoriasis Area and Severity Index and health‐related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate‐to‐severe plaque psoriasis. Journal Of The European Academy Of Dermatology And Venereology 2022, 36: 855-865. PMID: 35174556, PMCID: PMC9314097, DOI: 10.1111/jdv.18010.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexSevere plaque psoriasisHealth-related qualityRisankizumab treatmentPlaque psoriasisAbsolute PASIDLQI 0/1Psoriasis AreaDLQI scoreAbsolute PASI scoreAbsolute Psoriasis AreaUstekinumab-treated patientsMean DLQI scoreSeverity Index (PASI) improvementLife Quality IndexHigh ratePASI levelsPatients' HRQoL.PASI scoreMedian timeDurable efficacyPat ientsRisankizumabPASIPatients
2020
16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis
Gordon K, Bachelez H, Blauvelt A, Strober B, Harbers S, Valdes J, Waterhouse B, Sinvhal R, Lebwohl M, Reich K. 16332 Pooled long-term safety analysis of risankizumab in patients with moderate to severe psoriasis. Journal Of The American Academy Of Dermatology 2020, 83: ab176. DOI: 10.1016/j.jaad.2020.06.793.Peer-Reviewed Original Research
2017
Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis
Strober B, Papp K, Flack M, Gu Y, Thompson E, Valdecantos W. Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis. SKIN The Journal Of Cutaneous Medicine 2017, 1: s10. DOI: 10.25251/skin.1.supp.9.Peer-Reviewed Original Research